secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-06-03T22:43:26+00:00
Accession:  0001714899-26-000074
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved
--------------------------------------------------------------------------------

- Elected three Class III directors: Jennifer Cook, David Schenkein, Ryan Watts; broker non-votes ~13.1M.
- Ratified Ernst & Young as auditor for FY2026: 137.5M for, 420K against, 49.6K abstain.
- Non-binding advisory vote on executive compensation approved: 117.0M for, 7.1M against, 717.7K abstain.
- Quorum of 86.96% of outstanding shares (137.99M of 158.68M) represented at meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/0001714899-26-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/dnli-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer